[HTML][HTML] A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19
Background Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the …
respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the …
Diagnostic testing for severe acute respiratory syndrome–related coronavirus 2: a narrative review
Diagnostic testing to identify persons infected with severe acute respiratory syndrome–related
coronavirus 2 (SARS-CoV-2) infection is central to control the global pandemic of COVID-…
coronavirus 2 (SARS-CoV-2) infection is central to control the global pandemic of COVID-…
Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial
…, AA Nascene, KH Hullsiek, MP Cheng… - Annals of internal …, 2020 - acpjournals.org
Background: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in …
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in …
[HTML][HTML] Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
…, K Hager, A Mahmood, A Makarkov, MP Cheng… - Nature medicine, 2021 - nature.com
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being
deployed, but the global need greatly exceeds the supply, and different formulations might …
deployed, but the global need greatly exceeds the supply, and different formulations might …
[HTML][HTML] Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies
Background Our understanding of the global scale of Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data …
Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data …
Suppressed phase segregation for triple-junction perovskite solar cells
The tunable bandgaps and facile fabrication of perovskites make them attractive for multi-junction
photovoltaics 1 , 2 . However, light-induced phase segregation limits their efficiency …
photovoltaics 1 , 2 . However, light-induced phase segregation limits their efficiency …
[HTML][HTML] Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis
…, TG Evans, J Chevrier, J Papenburg, MP Cheng - PloS one, 2021 - journals.plos.org
Background Many studies report the seroprevalence of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) antibodies. We aimed to synthesize seroprevalence data to …
coronavirus 2 (SARS-CoV-2) antibodies. We aimed to synthesize seroprevalence data to …
[HTML][HTML] Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial
…, FM Carrier, YA Cavayas, N Chagnon, MP Cheng… - Cmaj, 2022 - Can Med Assoc
Background: The role of remdesivir in the treatment of patients in hospital with COVID-19
remains ill defined in a global context. The World Health Organization Solidarity randomized …
remains ill defined in a global context. The World Health Organization Solidarity randomized …
[HTML][HTML] SeroTracker: a global SARS-CoV-2 seroprevalence dashboard
…, T Yan, N Bobrovitz, J Chevrier, MP Cheng… - The Lancet Infectious …, 2021 - thelancet.com
As the initial phase of the COVID-19 pandemic passes its peak in many countries, serological
studies are becoming increasingly important in guiding public health responses. Antibody …
studies are becoming increasingly important in guiding public health responses. Antibody …
Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus 2: A Narrative Review
Accurate serologic tests to detect host antibodies to severe acute respiratory syndrome–related
coronavirus 2 (SARS-CoV-2) will be critical for the public health response to the …
coronavirus 2 (SARS-CoV-2) will be critical for the public health response to the …